Simon MEGY
Equipe : Groupe EcMo
Courriel : simon.megy@ibcp.fr
Téléphone : +33(0)4-72-72-26-55
Statut : Maître de conférences
12 publications au total. Seules les 5 dernières années sont affichées
2023
12. Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus.
Lamrayah M, Charriaud F, Desmares M, Coiffier C, Megy S, Colomb E, Terreux R, Lucifora J, Durantel D, Verrier B
(2023) Antiviral Res 209 :105483-105483
2021
11. Discovery of a Novel Non-Narcotic Analgesic Derived from the CL-20 Explosive: Synthesis, Pharmacology, and Target Identification of Thiowurtzine, a Potent Inhibitor of the Opioid Receptors and the Ion Channels.
Aguero S, Megy S, Eremina Vv, Kalashnikov Ai, Krylova Sg, Kulagina Da, Lopatina Ka, Fournier M, Povetyeva Tn, Vorozhtsov Ab, Sysolyatin Sv, Zhdanov Vv, Terreux R
(2021) Acs Omega 6 :15400-15411
10. Surface charge modulation of rifampicin-loaded PLA nanoparticles to improve antibiotic delivery in Staphylococcus aureus biofilms.
Da Costa D, Exbrayat-héritier C, Rambaud B, Megy S, Terreux R, Verrier B, Primard C
(2021) J Nanobiotechnology 19 :12-12
2020
9. Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam1CSK4 and Pam3CSK4.
Megy S, Aguero S, Da Costa D, Lamrayah M, Berthet M, Primard C, Verrier B, Terreux R
(2020) Nanomaterials (basel) 10 :
